Overview

- Introduction
- Benefits
- Indications and Usage
- How it Works
- Dosage & Administration
- Side Effects
- Warning and Precaution
- Patient Guidance
- Clinical Trial & Approvals
- References
- FAQ

Bernila Santos is a licensed pharmacist specializing in clinical pharmacy, drug safety, and pharmaceutical content review. With over a decade of experience in pharmacology, medication management, and regulatory compliance, she is committed to ensuring patients receive accurate and safe medical information. Ms. Santos has worked in hospital pharmacies, pharmaceutical research, and regulatory affairs.

Tibsovo 250 mg oral tablet used for IDH1-mutated AML

Tibsovo 250 mg Tablet

Q: Who can benefit from Tibsovo?

Adult patients with cancers that test positive for the IDH1 mutation, including AML, MDS, or cholangiocarcinoma.

Q: How quickly can Tibsovo work?

Patients may experience improvements within weeks; the effect and duration depend on the individual’s response and the disease.

Q: What if I miss a dose?

Take a missed dose within 12 hours; if more than 12 hours have passed, skip the dose and resume the next scheduled dose. Do not double-dose.

Q: Can I take it with food?

Yes, you can take it with or without food, but stay consistent each day.

Q: What should I avoid while taking Tibsovo?

Avoid high-fat food at the same time as taking your dose of Tibsovo. Follow your doctor’s instructions about any restrictions on food, beverages, or activity.

Q: Is Tibsovo (ivosidenib) chemotherapy?

No, Tibsovo is not traditional chemotherapy. It is a targeted therapy known as an IDH1 inhibitor, designed to block a specific genetic mutation (IDH1) found in some cancer cells.

Q: Can I take Tibsovo if I have AML, MDS, or bile duct cancer but don’t have an IDH1 mutation?

No. Tibsovo is only effective in patients whose cancer tests positive for the IDH1 mutation. It is not recommended for use in patients without the IDH1 mutation, as the drug targets that specific abnormal protein.

Q: Can Tibsovo be used for brain cancer?

Tibsovo is not currently approved for brain cancer. However, IDH1 mutations are found in some brain tumors like gliomas, and research is ongoing. Discuss clinical trial options with your oncologist if applicable.

Q: Can Tibsovo cause joint pain?

Yes, joint pain (arthralgia) is a known side effect of Tibsovo. Other musculoskeletal symptoms may also occur. Let your healthcare provider know if pain becomes severe or persistent.

Q: Does Tibsovo cause heart problems?

Tibsovo may cause QT prolongation, a change in heart rhythm that can be serious. Your doctor may perform ECGs (electrocardiograms) before and during treatment to monitor your heart function.

Prescription Required

Brand Name:

Tibsovo

Molecule:

Ivosidenib

Strength:

250 mg

Quantity:

60 Tablets

Form:

Tablet

Packaging Type:

Bottle

Manufacturer/Marketed By:

Servier

Country of Origin:

USA

Categories: Blood Cancer, Cholangiocarcinoma, Oncology

Product	Manufacturer / Marketed By	Price
Lucivos 250 mg Tablet	Lucius Pharma	Ask for Price
Ivosenib 250 mg Tablet	Everest Pharma	Ask for Price

Description

Tibsovo 250 mg is an oral, targeted cancer therapy that contains ivosidenib, a first-in-class IDH1 inhibitor. This medication is designed to treat cancers driven by a specific mutation in the isocitrate dehydrogenase-1 (IDH1) gene, a mutation that leads to the overproduction of an abnormal metabolite called 2-hydroxyglutarate (2-HG). Excess 2-HG interferes with normal cell differentiation, allowing cancer cells to grow uncontrollably. By selectively blocking the mutated IDH1 enzyme, Tibsovo helps restore healthy cellular function and encourages the maturation of cancerous cells into normal ones, a unique approach known as differentiation therapy. Each tablet delivers 250 mg of ivosidenib, taken once daily, offering a convenient and effective treatment option as part of personalized cancer care.

Tibsovo is approved to treat several IDH1 mutation–positive cancers:

Acute Myeloid Leukemia (AML): For newly diagnosed and relapsed/refractory cases
Myelodysplastic Syndrome (MDS): Specifically for relapsed/refractory disease
Cholangiocarcinoma: For advanced or metastatic bile duct cancer after prior therapy

Tibsovo represents a significant advancement in precision oncology, targeting the root molecular cause of the disease rather than just the symptoms.

Benefits

Precision Treatment: Reduces toxic oncometabolite levels by selectively blocking mutant IDH1 activity, supporting cancer cell differentiation
Extended Survival in AML: In the AGILE Phase 3 trial, combining Tibsovo with azacitidine improved event-free and overall survival in elderly AML patients
Oral Convenience: Once-daily pill promotes consistent adherence and ease of home treatment.
First-in-Class Therapy: The first targeted treatment explicitly approved for IDH1-mutated malignancies

Indications and Usage

Tibsovo 250 mg (ivosidenib) is indicated for the treatment of adult patients whose cancers are driven by a confirmed IDH1 gene mutation. This genetic alteration promotes the growth of cancer cells through abnormal metabolic activity. Genetic testing is required to confirm the presence of the IDH1 mutation before initiating treatment.

Approved Indications

1. Acute Myeloid Leukemia (AML)

Tibsovo is approved for adult patients with IDH1-mutated AML in the following settings:

Newly Diagnosed AML
For patients aged 75 years or older, or those with comorbidities that make them ineligible for intensive chemotherapy.
➤ Tibsovo may be used alone (monotherapy) or in combination with azacitidine, a hypomethylating agent.
Relapsed or Refractory AML
For patients whose disease has returned after treatment or has not responded to previous therapy.
➤ Tibsovo offers a targeted option with the potential for remission through cellular differentiation.

2. Myelodysplastic Syndrome (MDS)

Approved for patients with relapsed or refractory MDS that tests positive for an IDH1 mutation.
➤ Tibsovo provides a therapeutic option when standard treatments have failed or are poorly tolerated.

3. Cholangiocarcinoma (Bile Duct Cancer)

For adults with locally advanced or metastatic cholangiocarcinoma that has progressed after at least one prior systemic therapy.
➤ This indication makes Tibsovo the first FDA-approved targeted therapy for IDH1-mutated cholangiocarcinoma.

Off-Label and Investigational Use

IDH1-Mutated Gliomas (Low-Grade or Recurrent)
While not yet FDA-approved for this use, Tibsovo is being studied in clinical trials for IDH1-positive gliomas. Preliminary data suggest its potential to reduce tumor growth and delay progression, especially in low-grade brain tumors with 2–HG–dependent metabolic profiles.

How it Works

Tibsovo (ivosidenib) is a targeted therapy designed to treat cancers that carry a mutation in the IDH1 (isocitrate dehydrogenase 1) gene. In healthy cells, IDH1 plays a role in normal cellular metabolism. However, when mutated, it produces an abnormal enzyme that converts a natural substance into a harmful byproduct called 2-hydroxyglutarate (2-HG).

Why This Matters:

Elevated 2-HG levels disrupt the normal development (differentiation) of blood and tissue cells, causing them to remain immature and multiply uncontrollably, hallmarks of cancer.
Tibsovo works by selectively inhibiting the mutated IDH1 enzyme, preventing the formation of 2-HG.
This allows immature cancer cells to resume normal maturation, a treatment approach known as differentiation therapy.
Over time, Tibsovo can reduce tumor burden, restore healthy blood cell production, or slow tumor progression in solid cancers, such as cholangiocarcinoma.

Dosage & Administration

Standard Dose

250 mg once daily, taken by mouth with a full glass of water.
You can take Tibsovo with or without food, but it is recommended to take it at the same time each day for optimal results.

With Azacitidine (for AML)

In newly diagnosed AML patients, Tibsovo is often given in combination with azacitidine, a drug that helps control abnormal blood cell growth.
Ivosidenib is administered daily, while azacitidine is given in cycles (typically 7 days per month via injection or infusion).

Treatment Duration

Continue Tibsovo as long as it is effective and well-tolerated.
Your doctor will regularly monitor your progress with blood tests, ECGs, and imaging, adjusting treatment as needed.

Dose Modifications

Your healthcare provider may pause treatment or reduce the dose (to 250 mg every other day) if you experience severe side effects such as:
- QT interval prolongation (abnormal heart rhythm)
- Liver enzyme elevation
- Differentiation syndrome
After symptoms resolve or lab values normalize, your doctor may resume or modify your dosing schedule.

Important Tips

Do not split, crush, or chew the tablet.
If you miss a dose, take it as soon as you remember if it’s within 12 hours. If more than 12 hours have passed, skip the missed dose and continue with your regular schedule.

Do not double your dose to make up for a missed one.

Side Effects

Like all medications, Tibsovo may cause side effects. While many are mild and manageable, some may be serious and require immediate medical attention. Regular monitoring and open communication with your healthcare provider can help you stay safe and informed during treatment.

Common Side Effects (≥10% of patients)

These side effects occur frequently and are usually mild to moderate in severity:

Fatigue – Feeling unusually tired or weak
Nausea – Upset stomach, may improve with food or anti-nausea medication
Diarrhea or Constipation – Digestive changes are common and may fluctuate during treatment
Cough – Often mild, but report if persistent or worsening

Your doctor may recommend supportive care measures or dose adjustments if these symptoms significantly interfere with your daily life.

Serious Side Effects (≤10% of patients)

While less common, the following side effects can be severe and require prompt intervention:

Differentiation Syndrome

A potentially life-threatening reaction occurs as rapid changes in the cancer cells begin to mature.
Symptoms may include:
- Fever
- Weight gain or swelling
- Shortness of breath
- Low blood pressure
- Lung or kidney complications
Treatment: Immediate use of corticosteroids and/or pausing Tibsovo until symptoms resolve.
➤ Contact your doctor immediately if you experience these symptoms.

QT Prolongation (Heart Rhythm Changes)

Tibsovo may affect your heart’s electrical activity, leading to an abnormal rhythm.
Symptoms may include:
- Dizziness or lightheadedness
- Fainting
- Irregular heartbeat
Your healthcare provider will monitor your ECG (electrocardiogram) and electrolyte levels before and during treatment.

Electrolyte Imbalances & Liver Changes

Tibsovo can cause low potassium or magnesium levels, as well as elevated liver enzymes.
Regular blood tests help detect these early and guide dose adjustments or additional treatment.

Report any severe, unusual, or persistent symptoms to your healthcare provider immediately. Early detection and management of side effects can help prevent complications and keep you on track

Warning and Precaution

To ensure safe and effective use of Tibsovo, patients and healthcare providers must consider several key precautions:

Genetic Testing (Mandatory)

Before starting Tibsovo, patients must undergo a validated diagnostic test to confirm the presence of an IDH1 mutation.
Treatment is only indicated for IDH1-positive cancers; its use in IDH1-negative tumors may not be beneficial and could pose unnecessary risks.

ECG & Laboratory Monitoring

ECG (Electrocardiogram):
Monitor the QT interval at baseline, on days 8 and 15, and then monthly to detect heart rhythm abnormalities.
Blood Tests:
Regularly check liver function, electrolytes (including potassium, magnesium, and calcium), and complete blood count to detect side effects early and adjust dosing as needed.

Drug Interactions

Tibsovo is metabolized by the CYP3A4 enzyme in the liver, making it susceptible to interactions with other medications that also involve this enzyme.
Avoid potent CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin) and inducers (e.g., rifampin, carbamazepine), which can significantly affect drug levels and increase the risk of toxicity or treatment failure.
Review all prescription and over-the-counter drugs, supplements, and herbal products with your doctor before starting treatment.

Pregnancy and Breastfeeding Warning

Tibsovo may harm an unborn baby. Use effective contraception during treatment and for at least:
- 1 month after the last dose (females)
- 1 month after the last dose (male partners with female partners of childbearing potential)

Avoid breastfeeding during treatment and for at least 1 week after the last dose due to the unknown risk to infants.

Patient Guidance

Proper storage and handling of Tibsovo 250 mg ensure the medication remains safe and effective throughout its use. Follow these recommendations:

Storage Instructions

Store Tibsovo at room temperature, between 20°C and 25°C (68°F to 77°F).
Keep the medication in a cool, dry place, away from heat, moisture, and direct sunlight. Avoid storing in bathrooms or near kitchen sinks.

Handling Guidelines

Always keep the tablets in their original prescription bottle, which contains a desiccant (moisture-absorbing packet) to protect the medication from humidity.
Do not transfer tablets to another container or remove the desiccant.
Do not use tablets that appear damaged, chipped, discolored, or expired.

Safe Disposal

Do not flush unused or expired Tibsovo tablets down the toilet.
Dispose of them through a medicine take-back program, or ask your pharmacist or local waste authority for safe disposal options.

Safety Measures

Keep Tibsovo out of the reach of children and pets.
This medication is prescribed specifically for you—do not share it with others, even if they have similar symptoms or diagnoses.

Clinical Trial & Approvals

Tibsovo (ivosidenib) has undergone extensive clinical evaluation, leading to multiple FDA approvals based on its ability to improve outcomes in IDH1-mutated cancers.

FDA Approvals

2018 – Initial FDA Approval

Indication: Relapsed or refractory acute myeloid leukemia (AML) with an IDH1 mutation.
Significance: First IDH1 inhibitor approved by the FDA, introducing a new era of precision oncology for AML.

2019 – Expanded Indication

Indication: Newly diagnosed AML in patients aged ≥75 years or those with comorbidities that prevent the use of intensive chemotherapy.
Combination: Tibsovo is approved for use in combination with azacitidine in this population.

2021 – Approval for Solid Tumors

Indication: Previously treated, IDH1-mutated cholangiocarcinoma (bile duct cancer).

Importance: Tibsovo became the first targeted therapy explicitly approved for cholangiocarcinoma with an IDH1 mutation.

Key Clinical Trials

AGILE Trial (Phase 3) – AML

Population: Patients with newly diagnosed IDH1-mutated AML ineligible for standard chemotherapy.
Results:
- Tibsovo, in combination with azacitidine, significantly improved event-free survival and overall survival.
- Showed higher rates of complete remission compared to azacitidine alone.
Status: Supported expanded FDA approval and solidified Tibsovo’s role as a frontline therapy for this subset of AML patients.